Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation NIHR HSRIC. Atezolizumab for urothelial bladder cancer – second and subsequent line. Birmingham: NIHR Horizon Scanning Research&Intelligence Centre. Horizon Scanning Review. 2015 Authors' objectives Atezolizumab is intended to be used as second and subsequent line therapy for the treatment of locally advanced or metastatic urothelial bladder cancer. If licensed, it will provide an additional treatment option for this patient group. Atezolizumab is a monoclonal antibody targeting programmed cell death-1 ligand (PD-L1 or CD274 antigen) that acts as an immune check-point inhibitor. Atezolizumab does not currently have Marketing Authorisation in the EU for any indication.
Bladder cancer is the seventh most common cancer in the UK, accounting for 3% of new cases. There were 8,858 new diagnoses in England in 2011, equating to an age-standardised incidence rate of 11.1 per 100,000 population. Survival is dependent on the stage of the disease at diagnosis. One-year survival for locally advanced disease is 59% and 38% for men and women respectively; for metastatic disease, one-year survival is 26% and 25% for men and women respectively.
Treatment options for urothelial bladder cancer are dependent on the stage of disease, tumour size, and the general health of the patient. Current second line treatment options for locally advanced or metastatic bladder cancer include chemotherapy (including gemcitabine with cisplatin, and carboplatin or gemcitabine with paclitaxel), surgery, and radiotherapy. Atezolizumab is currently in phase III clinical trials comparing its effect on overall survival against treatment with chemotherapy. Indexing Status Subject indexing assigned by CRD MeSH Carcinoma, Transitional Cell; Humans; Urinary Bladder Neoplasms; Urologic Neoplasms Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NIHR Horizon Scanning Research&Intelligence Centre, University of Birmingham, Institute of Applied Health Research, Public Health building, Edgbaston, Birmingham B15 2TT
Tel: 0121 414 9077 Email: nihrhsc@contacts.bham.ac.uk AccessionNumber 32016000351 Date abstract record published 03/03/2016 |